Overview
NNVC market data
Price History
NNVC price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.74 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.87 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.85 – $2.23 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $34.8M · P/B 2.99.
Company News
NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For EbolaBenzinga · Aug 10, 2026, 12:34 PM
NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of CongoBenzinga · Jul 28, 2026, 12:35 PM
NanoViricides shares are trading lower after the company announced the pricing of its approximately $3.8 million offering of 2,516,339 shares.Benzinga · Jul 24, 2026, 12:34 PM
NanoViricides Prices ~$3.8 Million Registered Direct Offering Of 2,516,339 SharesBenzinga · Jul 24, 2026, 12:02 PM
NanoVricides Applies To DRC Regulatory Agency ACOREP For Approval To Begin A Phase II Clinical Trial Of NV-387 Oral Gummies To Treat The Current Bundibugyo EbolavirusBenzinga · Jul 22, 2026, 12:33 PM
8-K filing — NANOVIRICIDES, INC. (NNVC)SEC EDGAR · Jul 17, 2026, 8:45 PM
NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gummies To Treat Current Bundibugyo Ebolavirus In CongoBenzinga · Jul 13, 2026, 1:28 PM
Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Target of $6Benzinga · Jul 6, 2026, 6:00 PM
NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Trial Of NV-387 Oral Gummies Formulation As Treatment For Current Bundibugyo Ebolavirus In DRCBenzinga · Jul 6, 2026, 12:45 PM
FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoViricides' Antiviral Drug NV-387Benzinga · Jun 29, 2026, 12:45 PM